LiverSource »  Faculty »  Medical Oncology »  Andrew H. Ko, M.D.
Andrew H. Ko, M.D.

Andrew H. Ko, M.D.

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine

Contact Information

UCSF Comprehensive Cancer Center
1600 Divisadero St, 4th floor , Box 1705
San Francisco, CA 94115
(415) 353-9888  Appointments
(415) 353-9959  Fax
andrewko@medicine.ucsf.edu
Open Popup
  • Brown University, Providence, RI, Sc.B., 1991, Applied Mathematics/Biology
  • Johns Hopkins School of Medicine, Baltimore, MD, M.D., 1995, Medicine
  • 1995-1996, Beth Israel Hospital (Boston, MA), intern, Department of Internal Medicine
  • 1996-1998, Beth Israel Hospital (Boston, MA), resident, Department of Internal Medicine
  • 1998-2001, Stanford University School of Medicine, fellow, Division of Medical Oncology
  • American Board of Internal Medicine: Internal Medicine, Medical Oncology
  • Department of Medicine, Division of Hematology Oncology
  • Thoracic Oncology Program\
  • Member, UCSF Comprehensive Cancer Center
  • Barrett's Esophagus
  • Cholangiocarcinoma
  • Colon Cancer
  • Esophageal Cancer
  • Gall Bladder Cancer
  • Hepatocellular Carcinoma (Liver Cancer)
  • Lynch Syndrome
  • Neuroendocrine Tumors
  • Pancreatic Cancer
  • Rectal Cancer
  • Small Intestine Cancer
  • Stomach Cancer
  • Esophageal cancer
  • Pancreatic cancer
  • Signal transduction pathways in gastrointestinal development
  • Targeted therapies

Andrew H. Ko, M.D. specializes in the treatment of malignancies of the gastrointestinal tract, including esophageal, stomach, colorectal, pancreatic, and hepatobiliary cancers. Dr. Ko graduated magna cum laude from Brown University and received his medical degree from Johns Hopkins School of Medicine. After an internship and residency at Beth Israel Hospital in Boston, he completed a fellowship in medical oncology at Stanford University before joining the UCSF faculty in 2001.

Dr. Ko regularly presents patient cases at the Thoracic Oncology and GI Tumor Boards. He is a frequent lecturer in the GI cancer field and has served as Principal Investigator for trials using novel agents in esophageal and GI cancers. Dr. Ko holds memberships in numerous professional organizations and is a member of the Protocol Review and Data and Safety Monitoring committees at UCSF.

  1. Ko AH, Crane CH. Radiation therapy in operable and locally advanced pancreatic cancer. J Natl Compr Canc Netw. 2010 Oct; 8(9):1022-31.
  2. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7.
  3. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 1; 15(17):5569-75.
  4. Ko AH, Tempero MA. Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology. 2009 Jan; 136(1):43-5.
  5. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008 Oct; 37(3):269-74. View in: PubMed

X